JP2005534661A5 - - Google Patents

Download PDF

Info

Publication number
JP2005534661A5
JP2005534661A5 JP2004511295A JP2004511295A JP2005534661A5 JP 2005534661 A5 JP2005534661 A5 JP 2005534661A5 JP 2004511295 A JP2004511295 A JP 2004511295A JP 2004511295 A JP2004511295 A JP 2004511295A JP 2005534661 A5 JP2005534661 A5 JP 2005534661A5
Authority
JP
Japan
Prior art keywords
disease
injury
peripheral
alopecia
metastases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004511295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005534661A (ja
JP4437075B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/FR2003/001685 external-priority patent/WO2003104225A1/fr
Publication of JP2005534661A publication Critical patent/JP2005534661A/ja
Publication of JP2005534661A5 publication Critical patent/JP2005534661A5/ja
Application granted granted Critical
Publication of JP4437075B2 publication Critical patent/JP4437075B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004511295A 2002-06-07 2003-06-05 ピペラジニルアシルピペリジン誘導体、それらの製造方法およびそれらの治療的用途 Expired - Fee Related JP4437075B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207001 2002-06-07
PCT/FR2003/001685 WO2003104225A1 (fr) 2002-06-07 2003-06-05 Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique

Publications (3)

Publication Number Publication Date
JP2005534661A JP2005534661A (ja) 2005-11-17
JP2005534661A5 true JP2005534661A5 (https=) 2006-05-11
JP4437075B2 JP4437075B2 (ja) 2010-03-24

Family

ID=29724874

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004511296A Expired - Fee Related JP4441401B2 (ja) 2002-06-07 2003-06-05 ピペラジニルアシルピペリジン誘導体、それらの製造およびそれらの治療的用途
JP2004511295A Expired - Fee Related JP4437075B2 (ja) 2002-06-07 2003-06-05 ピペラジニルアシルピペリジン誘導体、それらの製造方法およびそれらの治療的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004511296A Expired - Fee Related JP4441401B2 (ja) 2002-06-07 2003-06-05 ピペラジニルアシルピペリジン誘導体、それらの製造およびそれらの治療的用途

Country Status (29)

Country Link
US (2) US7468368B2 (https=)
EP (2) EP1513835B1 (https=)
JP (2) JP4441401B2 (https=)
KR (1) KR100970812B1 (https=)
CN (1) CN100448875C (https=)
AR (2) AR040246A1 (https=)
AT (2) ATE336491T1 (https=)
AU (2) AU2003255645A1 (https=)
BR (1) BR0311828A (https=)
CA (1) CA2487840C (https=)
CY (2) CY1107330T1 (https=)
DE (2) DE60305037T2 (https=)
DK (2) DK1513835T3 (https=)
EA (1) EA007501B1 (https=)
ES (2) ES2264001T3 (https=)
HR (1) HRP20041157B1 (https=)
IS (1) IS2302B (https=)
MA (1) MA27233A1 (https=)
ME (1) MEP11508A (https=)
MX (1) MXPA04012341A (https=)
NO (1) NO329669B1 (https=)
NZ (1) NZ537044A (https=)
PL (1) PL208711B1 (https=)
PT (2) PT1513835E (https=)
RS (2) RS52588B (https=)
TW (2) TWI283671B (https=)
UA (1) UA77526C2 (https=)
WO (2) WO2003104226A1 (https=)
ZA (1) ZA200409823B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
US7723362B2 (en) * 2004-01-08 2010-05-25 Syngenta Crop Protection, Inc. Pesticidal heterocyclic dihaloallyl compounds
CA2572821A1 (en) * 2004-07-16 2006-01-26 Janssen Pharmaceutica N.V. Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitable for the treatment of neurodegenerative disorders
MX2007003318A (es) * 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
EP2586445A1 (en) * 2005-04-15 2013-05-01 University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
KR20100049500A (ko) * 2007-03-15 2010-05-12 쉐링 코포레이션 글루칸 신타제 억제제로서 유용한 피리다지논 유도체
JP5466147B2 (ja) * 2007-05-21 2014-04-09 レビバ ファーマシューティカルズ,インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2932481B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
EP3470402B1 (en) 2009-11-12 2021-01-06 Pharmatrophix Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
MX2012006776A (es) 2009-12-14 2012-10-05 Merck Patent Gmbh Inhibidores de la esfingosina quinasa.
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr) * 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
EP3684364A4 (en) * 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
MA71645A (fr) 2018-09-18 2025-05-30 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation
US12576033B2 (en) 2019-04-11 2026-03-17 Gfb (Abc), Llc Spray-dried formulation of a pyridazinone TRPC5 inhibitor
EP3858439A1 (en) * 2020-02-03 2021-08-04 Esteve Pharmaceuticals, S.A. Amide derivatives having multimodal activity against pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173180B (es) * 1987-10-26 1994-02-07 Pfizer Procedimiento para preparar agentes ansioliticos
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr) 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Similar Documents

Publication Publication Date Title
JP2005534661A5 (https=)
JP2005533051A5 (https=)
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
IL180979A (en) Isoindulin compounds and their use
WO2004080423A3 (en) 7-amino- isoindolyl compounds amd their pharmaceutical uses
SI2527315T1 (sl) Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
SI1660057T1 (sl) Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
TWI369987B (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
NO20054640D0 (no) Fremgangsmater for behandling av Parkinsons sykdom
EP1818325A3 (en) 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EP2279727A3 (en) Nanoparticulate aripiprazole formulations
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
TR200001795T2 (tr) 1-İkameli-1-Aminometil-sikloalkan türevleri (=Gabapentin analogları), bunların hazırlanması ve nörolojik bozuklukların tedavisinde kullanımı.
TW200745135A (en) Therapeutic agents
IL173351A0 (en) Therapy of ocular disorders
PL377715A1 (pl) Antagoniści CCR1 do leczenia między innymi demielizacyjnej choroby zapalnej
WO2008125902A3 (en) Peripheral and neural inflammatory crosstalk
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
EP1201240A3 (en) Heterocyclic derivatives useful as pharmaceutical agents